New hope for stomach cancer: drug combo aims to shrink tumors before surgery
NCT ID NCT07314203
First seen Jan 09, 2026 · Last updated May 03, 2026 · Updated 11 times
Summary
This study tests whether adding two drugs (adebrelimab and apatinib) to standard chemotherapy before surgery can help shrink advanced stomach cancer more effectively. About 118 adults with HER2-negative stomach cancer that cannot be removed right away will take part. The main goal is to see how many patients have no cancer left in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SURGERY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.